Straight Bat??16 Nov 2019 11:52
I used to disparage any conspiracy theories about Iclaprim, as did many other sensible posters (eg Ivy) but, after the last couple of years if this, you have to wonder. A short summary: things were going well until the NASDAQ float,. then we had all sorts of mysterious dealings such that even well-informed commentators, such as "Jimbo" had to admit to not having a clue to what was going on, even after the "greenshoes" business came into our sphere of knowledge. If anything, the weirdness of trading has become worse. Then we need to have an explanation for Scott, plugging away every day. He could be shorting but I suspect a shorter would have made so much he could have cashed in any time over the past year and bought his citizenship to Malta with small change. So perhaps he is an accumulator or working for an accumulator who knows how this will pan out? I can't see anything credible in any other interpretation - anger with the BoD, no..... no-one in finance is that silly. Then, a few months ago, I started reading about ulterior motives within the FDA and the mechanisms it uses to review applications - and I began to have doubts about its probity. There are lots of sources out there, some of them as crazy as blaming Yovanovitch for Black Hawk Down, but I reference what seems to be a sober one below. The take-home message, I conclude, is that cash can influence, in ways that would be very difficult for the authorities to "prove", the approval of a drug or, even more easily, the timing of that approval. There's a mountain of cash to be made here by the obvious manipulation that could theoretically have been performed here and, given Trump's USA, the steps that needed to be taken are hardly the stuff of a John Le Carre labrynth. Of course, it's just a possibility, and I'm not signing up for the Area 51 package deal as yet, but it's one of the reasons I am holding on until the fat lady sings (or the Ukranian squeals):
https://www.sciencemag.org/news/2018/07/hidden-conflicts-pharma-payments-fda-advisers-after-drug-approvals-spark-ethical
Sign In
Follow the stocks
